Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,173.9
9.1 (0.29%)

 

  • STI Straits Times Index
    3,173.9
    9.1 (0.29%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,598.3
    5.8 (0.36%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,331.0
    368.4 (1.48%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,572.4
    14.1 (0.40%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,068.6
    517.7 (1.81%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,633.3
    7.2 (0.11%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,492.6M
  • Value: 1,237.8M
  • Rise: 199
  • Fall: 127
  • Unch: 425

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.079+0.009
Rex Intl0.310+0.005
Genting Sing0.795+0.015
Ntegrator Intl0.009-
Geo Energy Res0.410-0.010
RH PetroGas0.205-
Sembcorp Marine0.080-
MarcoPolo Marine0.028-0.001
BlackGoldNatural0.019-
ThaiBev0.715+0.005

World Indices

World Indices
Name Last Change
Nasdaq 14,897.3 +73.9
HSI 25,331.0 +368.4
HSCEI 8,966.2 +117.0
Jakarta 6,633.3 +7.2
Nikkei 225 29,068.6 +517.7
SSE Comp 3,572.4 +14.1
Shanghai A 3,743.9 +14.8
Shanghai B 278.0 +0.5
KOSPI 3,015.1 +26.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IP INTER PHARMA PCL
Updated on 15 Oct 2021 (End of trading day)
Last (THB): 21.300 Change: -0.100 High: 21.700 Remarks: -
Change (%): -0.47 Low: 21.200
Open 21.600 Yesterday's Close 21.400000000000002
Buy Price 21.000 Sell Price 21.000
Buy Volume ('00) 91 Sell Volume ('00) 560
Cumulative Volume ('00) 3,921 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (THB) a 0.18045 Trailing EPS (THB) e 0.22289 NAV (THB) b 1.7104
PE a 118.038 Trailing PE f 95.563 Price / NAV b 12.4532
Dividend (THB) d 0.016179 Cash In Hand (THB) g 0.2747 Issued & Paid-up Shares c 298,013,000
Dividend Yield (%) d 0.076 Price / Cash In Hand g 77.539 Treasury Shares h -
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 6,347.677
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 6,421.835
Piotroski F Score 3 Exchange Code IP Par Value ( THB ) 0.50000
52 Weeks Volatility (%) 49.19 6-Month VWAP 20.815 Free Float (%) 37.1
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 20 Jul 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 04 Nov 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IP SET 6,347.677 118.038 95.563 12.4532 0.076
Industry Pharmaceuticals: Major SET 2,501.946 82.645 78.547 5.9468 0.520
Local Peer JCT SET 1,066.500 15.843 17.487 0.9091 4.430
Global Peer JOHNSON & JOHNSON NYSE 424,619.024 28.858 23.899 6.1026 2.467
Global Peer PFIZER INC NYSE 232,621.568 24.191 17.586 3.3212 3.662
Global Peer ELI LILLY AND COMPANY NYSE 227,551.488 36.739 37.484 35.3100 1.244
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 202,860.219 24.982 22.555 3.7538 2.313
Global Peer MERCK & CO INC NYSE 198,282.212 28.057 35.592 5.9555 3.165
Global Peer ABBVIE INC NYSE 193,205.789 42.407 29.322 15.3715 4.422
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 186,577.819 58.379 49.477 11.9021 1.928
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 181,403.790 28.152 25.482 17.3508 1.314
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 129,682.340 - - 3.5232 3.184
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 123,441.019 8.794 17.825 1.6460 2.738
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), REPLIGEN CORP (NASDAQ), INNOVENT BIOLOGICS INC (HKEx), CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ORGANON & CO (NYSE), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SINOPHARM GROUP CO. LTD. (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), AKESO INC (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), ADC THERAPEUTICS SA (NYSE), IGM BIOSCIENCES INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), EVEREST MEDICINES LTD (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), OCUMENSION THERAPEUTICS (HKEx), CSTONE PHARMACEUTICALS (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), ZYMEWORKS INC (NYSE), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ABBISKO CAYMAN LTD (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), Kimia Farma Tbk. (IDX), GOSSAMER BIO INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), IMMUNOTECH BIOPHARM LTD (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), KRONOS BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CK LIFE SCIENCES INTL HLDG (HKEx), KEROS THERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), ANTENGENE CORP LTD (HKEx), IDEAYA BIOSCIENCES INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), GH RESEARCH PLC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), VERU INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), HUA MEDICINE (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), WEREWOLF THERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), AC IMMUNE SA (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), EVELO BIOSCIENCES INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), CLENE INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), ESSA PHARMA INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), RACE ONCOLOGY LTD (ASX), SILVERBACK THERAPEUTICS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), BIOMEA FUSION INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), FUSION PHARMACEUTICALS INC (NASDAQ), CYBIN INC (NYSE American), TCR2 THERAPEUTICS INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), XOMA CORP (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), NEXIMMUNE INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), BSTEAD (Bursa), CHECKPOINT THERAPEUTICS INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), DURECT CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HARROW HEALTH INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), ANGION BIOMEDICA CORP (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TRICIDA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), OBSEVA SA (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), IMMUNIC INC (NASDAQ), ANNOVIS BIO INC (NYSE American), IMPEL NEUROPHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), INOZYME PHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), NOVAN INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), POLYPID LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), IX Biopharma (SGX), ENTERA BIO LTD (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), NOXOPHARM LTD (ASX), GENPREX INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), EDESA BIOTECH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), IMARA INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), YUMANITY THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), Phapros Tbk. (IDX), OCUPHIRE PHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), PAK FAH YEOW INTERNATIONAL (HKEx), Hyphens Pharma (SGX), MANNATECH INC (NASDAQ), NOVA (Bursa), ABVC BIOPHARMA INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), EXOPHARM LTD (ASX), VYNE THERAPEUTICS INC (NASDAQ), INVION LTD (ASX), BIOHLDG (Bursa), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), VIRPAX PHARMA INC (NASDAQ), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), SEQLL INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), PHARMAXIS (ASX), MEDLAB CLINICAL LIMITED (ASX), VIRIOS THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PALLA PHARMA LTD (ASX), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), SUNZEN (Bursa), NLS PHARMACEUTICS LTD (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TIMBER PHARMACEUTICALS INC (NYSE American), ACRUX (ASX), IMMURON LIMITED (ASX), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), PETROS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.600
-2.74 %
10 Days -+0.100
+0.47 %
20 Days --0.500
-2.29 %
Medium Term Return 3 Months --1.033
-4.63 %
6 Months -+1.209
+6.02 %
1 Year 0.023+13.368
+168.82 %
Annualised Return Annualised --
+168.82 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 6.932 - 23.600 Change From 1 Year Low +14.368 % Change From 1 Year Low (%) +207.27
Change From 1 Year High -2.300 % Change From 1 Year High (%) -9.75
2 Years Range 2.453 - 23.600 Change From 2 Years Low +18.847 % Change From 2 Years Low (%) +768.36
Change From 2 Years High -2.300 % Change From 2 Years High (%) -9.75
5 Years Range 2.453 - 23.600 Change From 5 Years Low +18.847 % Change From 5 Years Low (%) +768.36
Change From 5 Years High -2.300 % Change From 5 Years High (%) -9.75
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Inter Pharma PCL is engaged in biopharmaceutical business. It manufactures and distributes healthcare products including wellness and anti-aging products, aesthetic innovation products, companion animal health products, and livestock products. The company was founded on April 20, 2006 and is headquartered in Bangkok, Thailand.

Historical Price Data

Date Open High Low Close Volume VWAP
15 Oct 2021 21.600 21.700 21.200 21.300 392,100 21.3155
14 Oct 2021 21.200 21.600 21.200 21.400 178,800 21.4333
12 Oct 2021 21.600 21.600 21.200 21.200 345,000 21.3302
11 Oct 2021 22.000 22.000 21.500 21.600 305,100 21.7004
08 Oct 2021 21.800 22.000 21.800 21.900 321,600 21.8954
07 Oct 2021 21.700 22.100 21.700 21.800 463,500 21.8928
06 Oct 2021 21.500 21.800 21.500 21.600 119,200 21.6528
05 Oct 2021 21.600 21.800 21.500 21.500 111,900 21.6071
04 Oct 2021 21.200 21.600 21.200 21.500 329,200 21.5430
01 Oct 2021 21.100 21.400 20.900 21.200 606,100 21.1059
30 Sep 2021 21.200 21.400 21.200 21.300 241,200 21.2652
29 Sep 2021 21.400 21.500 21.200 21.300 387,100 21.3337
28 Sep 2021 21.300 21.600 21.100 21.500 422,700 21.3525
27 Sep 2021 21.700 21.700 21.300 21.300 602,800 21.4493
23 Sep 2021 21.800 22.000 21.600 21.600 448,200 21.6743
22 Sep 2021 22.300 22.300 21.800 21.800 544,000 22.0118
21 Sep 2021 21.600 22.200 21.500 22.200 1,230,500 22.0804
20 Sep 2021 21.600 22.000 21.500 21.600 452,300 21.6642
17 Sep 2021 22.200 22.400 21.800 21.800 805,100 22.0561
16 Sep 2021 21.500 22.200 21.300 22.100 811,500 21.8970
15 Sep 2021 21.100 21.600 21.100 21.300 482,400 21.3707
14 Sep 2021 21.800 21.800 21.300 21.300 667,300 21.4351
Summary
Current 2 Weeks
(01 Oct 2021 to 15 Oct 2021)
21.100 22.100 20.900 21.300 3,172,500 -
Previous 2 Weeks
(16 Sep 2021 to 30 Sep 2021)
21.500 22.200 20.900 21.300 5,945,400 -
4 Weeks from
(19 Aug 2021 to 15 Sep 2021)
21.000 22.100 20.900 21.300 16,953,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.